- Rob Bancroft appointed as CEO of AEON Biopharma (AEON, Financial), effective April 29, 2025.
- AEON's ABP-450 program is progressing through FDA's 351(k) biosimilar regulatory pathway.
- ABP-450 aims to penetrate the $3B botulinum toxin therapeutics market as a comparable alternative to BOTOX.
AEON Biopharma (AEON) has announced the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Bancroft, with over 25 years of experience in the life sciences sector, will join AEON's Board of Directors. His notable previous roles include General Manager at Revance Therapeutics and leadership at Smith & Nephew's Biotherapeutics division.
This appointment comes as AEON advances its ABP-450 program through the 351(k) biosimilar regulatory pathway. Sharing the same 900kDa molecular weight as BOTOX, ABP-450 is designed to offer a clinically comparable alternative in the $3 billion botulinum toxin therapeutics market. The company plans to announce results from its Biosimilar BPD Type 2a FDA meeting in the latter half of 2025.
Bancroft's extensive background includes leading therapeutic strategy and commercialization efforts for products like BOTOX during his tenure at Allergan. As AEON sets its sights on expanding access to care for patients, Bancroft is poised to guide the company through the crucial stages of ABP-450's development and potential market entry.
